4/A: Mural Oncology Director Benjamin Hickey Corrects Stock Option Price in Amended SEC Filing

Benjamin Hickey, a director at Mural Oncology plc, filed an amended SEC Form 4 to correct the price of a stock option granted on May 30, 2024.

Summary

• Benjamin Hickey, a director of Mural Oncology plc, filed an amendment to a previously submitted Form 4 with the SEC.
• The purpose of the amendment is to correct a scrivener's error in the originally reported price of a stock option.
• The stock option, granting the right to buy 8,462 ordinary shares, was granted on May 30, 2024.
• The corrected price of the derivative security is $0.00, previously reported as $3.35.
• The option vests upon the earlier of the first anniversary of the grant date or the date of the next Annual Meeting, contingent on continued service with the Issuer.
• The option expires on May 29, 2034.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in reporting is always a positive.

Positives

• The amendment ensures accurate reporting of executive compensation.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also regularly grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedules and exercise prices of these options are typically structured to align executive incentives with shareholder value creation.

Stakeholder Impact

• Ensuring accurate reporting of executive compensation enhances transparency for shareholders.

Key Dates